Carlos M Galmarini

List of Publications by Year
in descending order

95 papers	7,026 citations	81889 39 h-index	58576 82 g-index
97 all docs	97 docs citations	97 times ranked	10730 citing authors

#	Article	IF	Citations
1	Drug Resistance and the Solid Tumor Microenvironment. Journal of the National Cancer Institute, 2007, 99, 1441-1454.	6.3	1,795
2	Role of Macrophage Targeting in the Antitumor Activity of Trabectedin. Cancer Cell, 2013, 23, 249-262.	16.8	721
3	Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncology, The, 2002, 3, 415-424.	10.7	494
4	A Review of Trabectedin (ET-743): A Unique Mechanism of Action. Molecular Cancer Therapeutics, 2010, 9, 2157-2163.	4.1	372
5	Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells. Cancer Research, 2010, 70, 2235-2244.	0.9	251
6	In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. British Journal of Haematology, 2002, 117, 860-868.	2.5	144
7	Unique features of trabectedin mechanism of action. Cancer Chemotherapy and Pharmacology, 2016, 77, 663-671.	2.3	132
8	Potential mechanisms of resistance to cytarabine in AML patients. Leukemia Research, 2002, 26, 621-629.	0.8	125
9	Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models. British Journal of Cancer, 2017, 117, 628-638.	6.4	119
10	Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells. Molecular Cancer Therapeutics, 2016, 15, 2399-2412.	4.1	111
11	Expression of a nonâ€functional p53 affects the sensitivity of cancer cells to gemcitabine. International Journal of Cancer, 2002, 97, 439-445.	5.1	92
12	Cancer chemotherapy: A critical analysis of its 60 years of history. Critical Reviews in Oncology/Hematology, 2012, 84, 181-199.	4.4	87
13	p53 as a target for anti-cancer drug development. Critical Reviews in Oncology/Hematology, 2006, 58, 190-207.	4.4	84
14	Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine. British Journal of Haematology, 2003, 122, 53-60.	2.5	83
15	Expression of high Km 5â€²-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia. Blood, 2001, 98, 1922-1926.	1.4	80
16	Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. Blood, 2009, 113, 3781-3791.	1.4	78
17	The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin. Oncotarget, 2015, 6, 18875-18890.	1.8	74
18	Translation Elongation Factor eEF1A2 is a Novel Anticancer Target for the Marine Natural Product Plitidepsin. Scientific Reports, 2016, 6, 35100.	3.3	71

#	Article	IF	Citations
19	Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations. Blood, 2005, 105, 767-774.	1.4	70
20	Molecular pharmacology and antitumor activity of ZalypsisÂ® in several human cancer cell lines. Biochemical Pharmacology, 2009, 78, 162-170.	4.4	69
21	ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line. Future Oncology, 2019, 15, 231-239.	2.4	69
22	Trabectedin and Its C Subunit Modified Analogue PM01183 Attenuate Nucleotide Excision Repair and Show Activity toward Platinum-Resistant Cells. Molecular Cancer Therapeutics, 2011, 10, 1481-1489.	4.1	68
23	Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. BMC Pharmacology, 2004, 4, 8.	0.4	62
24	Characterization of a Gemcitabine-Resistant Murine Leukemic Cell Line. Clinical Cancer Research, 2004, 10, 5614-5621.	7.0	60
25	Problems Related to Resistance to Cytarabine in Acute Myeloid Leukemia. Leukemia and Lymphoma, 2004, 45, 1123-1132.	1.3	60
26	Class III Î²-Tubulin Isotype Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-Agent Doxorubicin or Docetaxel. Clinical Cancer Research, 2008, 14, 4511-4516.	7.0	58
27	Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells. Molecular Cancer Therapeutics, 2005, 4, 1268-1276.	4.1	57
28	New Interfacial Microtubule Inhibitors of Marine Origin, PM050489/PM060184, with Potent Antitumor Activity and a Distinct Mechanism. ACS Chemical Biology, 2013, 8, 2084-2094.	3.4	57
29	Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus. Cancer Research, 2016, 76, 6657-6668.	0.9	57
30	Temperature-induced melting of double-stranded DNA in the absence and presence of covalently bonded antitumour drugs: insight from molecular dynamics simulations. Nucleic Acids Research, 2011, 39, 8248-8257.	14.5	55
31	Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and ZalypsisÂ® (PM00104). International Journal of Cancer, 2013, 133, 2024-2033.	5.1	54
32	Indolobenzazepin-7-ones and 6-, 8-, and 9-Membered Ring Derivatives as Tubulin Polymerization Inhibitors: Synthesis and Structureâ^'Activity Relationship Studies. Journal of Medicinal Chemistry, 2009, 52, 5916-5925.	6.4	53
33	Pyrimidine nucleoside analogs in cancer treatment. Expert Review of Anticancer Therapy, 2003, 3, 717-728.	2.4	51
34	PM060184, a new tubulin binding agent with potent antitumor activity including P-glycoprotein over-expressing tumors. Biochemical Pharmacology, 2014, 88, 291-302.	4.4	49
35	Heterogeneous Distribution of Tumor Blood Supply Affects the Response to Chemotherapy in Patients with Head and Neck Cancer. Microcirculation, 2000, 7, 405-410.	1.8	48
36	XPF-Dependent DNA Breaks and RNA Polymerase II Arrest Induced by Antitumor DNA Interstrand Crosslinking-Mimetic Alkaloids. Chemistry and Biology, 2011, 18, 988-999.	6.0	46

#	Article	IF	Citations
37	Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy. Journal of Clinical Oncology, 2018, 36, 3134-3143.	1.6	43
38	Trabectedin and Plitidepsin: Drugs from the Sea that Strike the Tumor Microenvironment. Marine Drugs, 2014, 12, 719-733.	4.6	40
39	Synthesis and antiproliferative activity of clausine E, mukonine, and koenoline bioisosteres. Bioorganic and Medicinal Chemistry, 2007, 15, 5615-5619.	3.0	39
40	Predictive Factors of Sensitivity to Elisidepsin, a Novel Kahalalide F-Derived Marine Compound. Marine Drugs, 2013, 11, 944-959.	4.6	37
41	The prognostic value of cN-II and cN-III enzymes in adult acute myeloid leukemia. Haematologica, 2005, 90, 1699-701.	3.5	34
42	Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells. Cancer Chemotherapy and Pharmacology, 2006, 58, 547-554.	2.3	33
43	Polymeric nanogels containing the triphosphate form of cytotoxic nucleoside analogues show antitumor activity against breast and colorectal cancer cell lines. Molecular Cancer Therapeutics, 2008, 7, 3373-3380.	4.1	32
44	Synthesis and antiproliferative evaluation of pyrazolo[1,5-a]-1,3,5-triazine myoseverin derivatives. Bioorganic and Medicinal Chemistry, 2009, 17, 3471-3478.	3.0	32
45	CPâ€4055 and CPâ€4126 are active in araâ€C and gemcitabineâ€resistant lymphoma cell lines. British Journal of Haematology, 2009, 144, 273-275.	2.5	32
46	Role of IMP-SELECTIVE 5â€²-NUCLEOTIDASE (cN-II) in HEMATOLOGICAL MALIGNANCIES. Leukemia and Lymphoma, 2003, 44, 1105-1111.	1.3	28
47	The Antitumor Drugs Trabectedin and Lurbinectedin Induce Transcription-Dependent Replication Stress and Genome Instability. Molecular Cancer Research, 2019, 17, 773-782.	3.4	28
48	Frameshift mutation in the Dok1 gene in chronic lymphocytic leukemia. Oncogene, 2004, 23, 2287-2297.	5.9	26
49	The cytotoxic activity of Aplidin in chronic lymphocytic leukemia (CLL) is mediated by a direct effect on leukemic cells and an indirect effect on monocyte-derived cells. Investigational New Drugs, 2012, 30, 1830-1840.	2.6	26
50	Irvalec Inserts into the Plasma Membrane Causing Rapid Loss of Integrity and Necrotic Cell Death in Tumor Cells. PLoS ONE, 2011, 6, e19042.	2.5	26
51	Plocabulin, a novel tubulin-binding agent, inhibits angiogenesis by modulation of microtubule dynamics in endothelial cells. BMC Cancer, 2018, 18, 164.	2.6	25
52	In vitro susceptibility of CD4+ and CD8+ T cell subsets to fludarabine. Biochemical Pharmacology, 2003, 66, 2185-2191.	4.4	24
53	Binding of eEF1A2 to the RNA-dependent protein kinase PKR modulates its activity and promotes tumour cell survival. British Journal of Cancer, 2018, 119, 1410-1420.	6.4	24
54	Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair. Oncotarget, 2016, 7, 25885-25901.	1.8	24

#	Article	IF	Citations
55	Multidrug resistance in cancer therapy: role of the microenvironment. Current Opinion in Investigational Drugs, 2003, 4, 1416-21.	2.3	24
56	Mutational Targets in Colorectal Cancer Cells with Microsatellite Instability. Familial Cancer, 2006, 5, 29-34.	1.9	23
57	Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs. International Journal of Pharmaceutics, 2010, 395, 281-289.	5.2	23
58	Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts. Oncotarget, 2019, 10, 2709-2721.	1.8	23
59	The mechanism of action of plitidepsin. Current Opinion in Investigational Drugs, 2009, 10, 536-42.	2.3	23
60	Influence of p53 and p21WAF1 expression on sensitivity of cancer cells to cladribine. Biochemical Pharmacology, 2003, 65, 121-129.	4.4	22
61	Recent Developments to Improve the Efficacy of Cytotoxic Nucleoside Analogues. Recent Patents on Anti-Cancer Drug Discovery, 2006, 1, 163-170.	1.6	22
62	Lurbinectedin induces depletion of tumor-associated macrophages (TAM), an essential component of its in vivo synergism with gemcitabine. DMM Disease Models and Mechanisms, 2016, 9, 1461-1471.	2.4	21
63	Sensitization of ara-C-resistant lymphoma cells by a pronucleotide analogue. International Journal of Cancer, 2003, 107, 149-154.	5.1	20
64	Synergistic Effect of Trabectedin and Olaparib Combination Regimen in Breast Cancer Cell Lines. Journal of Breast Cancer, 2015, 18, 329.	1.9	20
65	Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms. British Journal of Cancer, 2017, 116, 335-343.	6.4	20
66	Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC). Leukemia and Lymphoma, 2005, 46, 335-346.	1.3	18
67	Modulation of the human equilibrative nucleoside transporter1 (hENT1) activity by IL-4 and PMA in B cells from chronic lymphocytic leukemia. Biochemical Pharmacology, 2008, 75, 857-865.	4.4	18
68	MI130004, a Novel Antibodyâ€“Drug Conjugate Combining Trastuzumab with a Molecule of Marine Origin, Shows Outstanding In Vivo Activity against HER2-Expressing Tumors. Molecular Cancer Therapeutics, 2018, 17, 786-794.	4.1	17
69	The Activity of the Lipophilic Nucleoside Derivatives Elacytarabine and CP-4126 in a Panel of Tumor Cell Lines Resistant to Nucleoside Analogues. Nucleosides, Nucleotides and Nucleic Acids, 2010, 29, 386-393.	1.1	16
70	Elisidepsin Interacts Directly with Glycosylceramides in the Plasma Membrane of Tumor Cells to Induce Necrotic Cell Death. PLoS ONE, 2015, 10, e0140782.	2.5	14
71	F-ara-AMP is a substrate of cytoplasmic 5â€²-nucleotidase II (cN-II): HPLC and NMR studies of enzymatic dephosphorylation. Nucleosides, Nucleotides and Nucleic Acids, 2006, 25, 289-297.	1.1	13
72	ErbB protein modifications are secondary to severe cell membrane alterations induced by elisidepsin treatment. European Journal of Pharmacology, 2011, 667, 91-99.	3.5	13

#	Article	IF	Citations
73	Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response. Haematologica, 2011, 96, 687-695.	3.5	13
74	Hypoxia Reduces the Efficiency of Elisidepsin by Inhibiting Hydroxylation and Altering the Structure of Lipid Rafts. Marine Drugs, 2013, 11, 4858-4875.	4.6	11
75	Concomitant resistance and early-breast cancer: should we change treatment strategies?. Cancer and Metastasis Reviews, 2014, 33, 271-283.	5.9	11
76	A p21/WAF1 mutation favors the appearance of drug resistance to paclitaxel in human noncancerous epithelial mammary cells. International Journal of Cancer, 2006, 119, 60-66.	5.1	10
77	Does p16ink4a expression increase with the number of cell doublings in normal and malignant lymphocytes?. Leukemia Research, 2007, 31, 1649-1658.	0.8	10
78	c-Jun N-Terminal Kinase Phosphorylation Is a Biomarker of Plitidepsin Activity. Marine Drugs, 2013, 11, 1677-1692.	4.6	10
79	Heterogeneous Distribution of Tumor Blood Supply Affects the Response to Chemotherapy in Patients with Head and Neck Cancer. Microcirculation, 2000, 7, 405-410.	1.8	10
80	Inhibitory effects of marineâ€derived DNAâ€binding antiâ€tumour tetrahydroisoquinolines on the Fanconi anaemia pathway. British Journal of Pharmacology, 2013, 170, 871-882.	5.4	9
81	Molecular basis of resistance to the microtubule-depolymerizing antitumor compound plocabulin. Scientific Reports, 2018, 8, 8616.	3.3	9
82	Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial. Gynecologic Oncology, 2014, 132, 176-180.	1.4	8
83	5'-(3')-nucleotidase mRNA levels in blast cells are a prognostic factor in acute myeloid leukemia patients treated with cytarabine. Haematologica, 2004, 89, 617-9.	3.5	8
84	Weekly administration of paclitaxel induces long-term aneugenicity in nude mice. Cancer Biology and Therapy, 2007, 6, 377-382.	3.4	7
85	P-glycoprotein expression by cancer cells affects cell cytotoxicity and cell-cycle perturbations induced by six chemotherapeutic drugs. Journal of Experimental Therapeutics and Oncology, 2002, 2, 146-152.	0.5	6
86	Survivorship in untreated breast cancer patients. Medical Oncology, 2015, 32, 466.	2.5	6
87	p21Cip1 regulates cellâ€“substrate adhesion and interphase microtubule dynamics in untransformed human mammary epithelial cells. European Journal of Cell Biology, 2011, 90, 631-641.	3.6	5
88	Î²III-Tubulin is required for interphase microtubule dynamics in untransformed human mammary epithelial cells. European Journal of Cell Biology, 2011, 90, 872-878.	3.6	5
89	Dynamic cellular maps of molecular species: Application to drug-target interactions. Scientific Reports, 2018, 8, 1140.	3.3	5
90	Lessons from Hippocrates: Time to Change the Cancer Paradigm. International Journal of Chronic Diseases, 2020, 2020, 1-14.	1.0	5

#	Article	IF	Citations
91	Abstract A174: Comparison of the antitumor activity of Trabectedin, Lurbinectedin, Zalypsis and PM00128 in a panel of human cells deficient in transcription/NER repair factors.. , 2013, , .		4
92	Abstract 5467: Role of the eukaryotic elongation factor eEF1A in the mechanism of action of Aplidin. , 2014, , .		2
93	Abstract 2129: Aplidin triggers the activation of molecular components of the UPR as part of its pro-apoptotic program in tumor cells.. , 2013, , .		1
94	Abstract 3066: Anti-angiogenic properties of PM060184. , 2016, , .		1
95	Why we do what we do. A brief analysis of cancer therapies. EXCLI Journal, 2020, 19, 1401-1413.	0.7	1